As its role in the immune response is more well-defined than NF-κB, targeting p53 LOF-mediated STAT3 activation to suppress both STAT3 and NF-κB pro-cancer signaling may be a viable approach to inducing an anti-tumor immune response. Here, NFKB1 is linked to cancer.